TMCI Treace Medical Concepts, Inc.
HealthcareAs of 2026-05-26
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.33
P/S
0.87
EV/EBITDA
-3.91
DCF Value
$-7.29
FCF Yield
-14.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
79.7%
Operating Margin
-26.9%
Net Margin
-29.4%
ROE
-69.5%
ROA
-33.2%
ROIC
-37.3%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $47.2M | $-18.0M | $— |
| Q4 null | $62.5M | $-9.4M | $— |
| FY null | $212.7M | $-59.0M | $— |
| Q3 null | $50.2M | $-16.3M | $— |
Analyst Ratings
View AllConsensus
Hold
Target (Consensus)
$3.00
Target (Median)
$3.00
Target Range
$3.00 - $3.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
1.11
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.